medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2020-11-32-35medalphabet-1540Research ArticleСтатьиПринципы медикаментозного лечения острого вестибулярного головокруженияDrug treatment of acute vertigoМасуеваС. С.MasuevaS. S.

аспирант кафедры неврологии

г. Москва

Moscow

ЗамерградМ. В.ZamergradM. V.

д. м. н., проф. кафедры1, н. с., врач-невролог

г. Москва

Moscow

Кафедра неврологии с курсом рефлексологии и мануальной терапии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian FederationРоссийский геронтологический научно-клинический центр ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова»РоссияPirogov Russian National Research Medical UniversityRussian Federation202015072020111Неврология и психиатрия3235Copyright © Масуева С.С., Замерград М.В., 20202020Масуева С.С., Замерград М.В.Masueva S.S., Zamergrad M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1540

Острое вестибулярное головокружение – тяжелое состояние, требующее неотложного лечения. Причинами истинного, или вестибулярного, головокружения обычно становятся расстройства периферического или центрального отделов вестибулярной системы, включающие различные по этиологии и патогенезу заболевания. Однако, независимо от происхождения, для острого периода вестибулярного головокружения характерны выраженные приступы, сопровождающиеся нарушением равновесия, тошнотой и рвотой. Симптоматическое лечение складывается из вестибулярных супрессантов и противорвотных препаратов. К основным принципам ведения пациентов с острым вестибулярным головокружением можно отнести совместное использование вестибулярных супрессантов и противорвотных средств, чем достигается потенцирование их эффектов, ограничение использования симптоматических средств 2–3 сутками и, возможно, более ранее начало вестибулярной реабилитации, эффективность которой можно повысить при помощи препаратов, стимулирующих центральную вестибулярную адаптацию.

Acute vertigo is a severe condition that requires urgent treatment. Vertigo can be caused by peripheral or central vestibular disorders of various etiopathology. Whatever the reason of vestibular dizziness, it is characterized by severe attacks with imbalance, nausea and vomiting in the acute period. Symptomatic treatment consists of vestibular suppressants and antiemetic drugs. There are several key principles regarding management of patients with vertigo that includes combined use of vestibular suppressants and antiemetics, which allows potentiation of their effects, limitation the use of symptomatic therapy to 2–3 days and perhaps earlier initiation of vestibular rehabilitation which effectiveness can be improved with agents that stimulate central vestibular adaptation.

головокружениевестибулярные нарушениялечениевестибулярные супрессантыпротиворвотные средстваvertigovestibular dysfunctionvestibular suppressantsantiemeticsReferencesЗамерград М. В., Парфенов В. А., Морозова С. В. и др. Периферические вестибулярные расстройства в амбулаторной практике. Вестник оториноларингологии. 2017; 82 (1): 30–33.Замерград М. В., Парфенов В. А., Морозова С. В. и др. Периферические вестибулярные расстройства в амбулаторной практике. Вестник оториноларингологии. 2017; 82 (1): 30–33.Брандт Т., Дитерих М., Штрупп М. Головокружение. М.: Практика; 2009.Брандт Т., Дитерих М., Штрупп М. Головокружение. М.: Практика; 2009.Smith P. F., Darlington C. L. Recent advances in the pharmacology of the vestibulo-ocular reflex system. Trends in Pharmacological Sciences. 1996 Nov; 17 (11): 421–427.Smith P. F., Darlington C. L. Recent advances in the pharmacology of the vestibulo-ocular reflex system. Trends in Pharmacological Sciences. 1996 Nov; 17 (11): 421–427.De Waele C., Mühlethaler M., Vidal P. P. Neurochemistry of the central vestibular pathways. Brain Research Reviews. 1995; 20 (1), 24–46.De Waele C., Mühlethaler M., Vidal P. P. Neurochemistry of the central vestibular pathways. Brain Research Reviews. 1995; 20 (1), 24–46.Barton J. J.S., Huaman A. G., Sharpe J. A. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: A double-blind, randomized trial of three intravenous drugs. Annals of Neurology. 1994; 35 (3), 319–325.Barton J. J.S., Huaman A. G., Sharpe J. A. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: A double-blind, randomized trial of three intravenous drugs. Annals of Neurology. 1994; 35 (3), 319–325.Zhu Y., Chen S.-R., Pan H.-L. Muscarinic receptor subtypes differentially control synaptic input and excitability of cerebellum-projecting medial vestibular nucleus neurons. Journal of Neurochemistry. 2016; 137 (2), 226–239.Zhu Y., Chen S.-R., Pan H.-L. Muscarinic receptor subtypes differentially control synaptic input and excitability of cerebellum-projecting medial vestibular nucleus neurons. Journal of Neurochemistry. 2016; 137 (2), 226–239.Takeda N., Morita M., Hasegawa S. et al. Neurochemical mechanisms of motion sickness. American Journal of Otolaryngology. 1989; 10(5), 351–359.Takeda N., Morita M., Hasegawa S. et al. Neurochemical mechanisms of motion sickness. American Journal of Otolaryngology. 1989; 10(5), 351–359.Lee C., Jones T. A. Neuropharmacological targets for drug action in vestibular sensory pathways. Journal of Audiology & Otology. 2017; 21 (3), 125–132.Lee C., Jones T. A. Neuropharmacological targets for drug action in vestibular sensory pathways. Journal of Audiology & Otology. 2017; 21 (3), 125–132.Smith P. F., Darlington CL. Pharmacology of the vestibular system. Bailliere’s Clinical Neurology. 1994; 3 (3): 467–84.Smith P. F., Darlington CL. Pharmacology of the vestibular system. Bailliere’s Clinical Neurology. 1994; 3 (3): 467–84.Cortes C., Galindo F., Galicia S. et al. Excitatory actions of GABA in developing chick vestibular afferents: Effects on resting electrical activity. Synapse. 2013; 67 (7), 374–381.Cortes C., Galindo F., Galicia S. et al. Excitatory actions of GABA in developing chick vestibular afferents: Effects on resting electrical activity. Synapse. 2013; 67 (7), 374–381.Desmadryl G., Gaboyard-Niay S., Brugeaud A. et al. Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. British Journal of Pharmacology. 2012 Oct; 167 (4): 905–916.Desmadryl G., Gaboyard-Niay S., Brugeaud A. et al. Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. British Journal of Pharmacology. 2012 Oct; 167 (4): 905–916.Tritto S., Botta L., Zampini V. et al. Calyx and dimorphic neurons of mouse Scarpa’s ganglion express histamine H3 receptors. BMC Neuroscience. 2009 Jun; 10 (1), 70.Tritto S., Botta L., Zampini V. et al. Calyx and dimorphic neurons of mouse Scarpa’s ganglion express histamine H3 receptors. BMC Neuroscience. 2009 Jun; 10 (1), 70.Tomoda K., Nagata M., Harada N. et al. Effect of histamine on intracellular Ca2+ concentration in guinea pig isolated vestibular hair cells. Acta Oto-laryngologica. 1997; 528: 37–40.Tomoda K., Nagata M., Harada N. et al. Effect of histamine on intracellular Ca2+ concentration in guinea pig isolated vestibular hair cells. Acta Oto-laryngologica. 1997; 528: 37–40.Serafin M., Khateb A., Waele C., et al. In vitro properties of medial vestibular neurones. In: Shimazu H., Shinoda Y. editors. Vestibular and brain stem control of eye, head, and body movements. Basel: Karger AG. 1992: 111–21.Serafin M., Khateb A., Waele C., et al. In vitro properties of medial vestibular neurones. In: Shimazu H., Shinoda Y. editors. Vestibular and brain stem control of eye, head, and body movements. Basel: Karger AG. 1992: 111–21.Wang J. J., Dutia M. B. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Experimental Brain Research. 1995; 105 (1): 18–24.Wang J. J., Dutia M. B. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Experimental Brain Research. 1995; 105 (1): 18–24.Dutia M. B. Betahistine, Vestibular function and compensation: In Vitro Studies of Vestibular Function and Plasticity. Acta Oto-laryngologica. 2000; 120 (544): 11–14.Dutia M. B. Betahistine, Vestibular function and compensation: In Vitro Studies of Vestibular Function and Plasticity. Acta Oto-laryngologica. 2000; 120 (544): 11–14.Takeda N., Morita M., Hasegawa S. et al. Neuropharmacology of motion sickness and emesis: a review. Acta Oto-laryngologica. 1993; 113 (sup. 501): 10–15.Takeda N., Morita M., Hasegawa S. et al. Neuropharmacology of motion sickness and emesis: a review. Acta Oto-laryngologica. 1993; 113 (sup. 501): 10–15.Kamen C., Tejani M. A., Chandwani K. et al. Anticipatory nausea and vomiting due to chemotherapy. European Journal of Pharmacology. 2014; 722: 172–179.Kamen C., Tejani M. A., Chandwani K. et al. Anticipatory nausea and vomiting due to chemotherapy. European Journal of Pharmacology. 2014; 722: 172–179.Шептулин А. А., Белоусова И. Б. Современные прокинетики и их роль в лечении гастроэнтерологических заболеваний. Клиническая медицина. 2016; 94 (3): 178–182.Шептулин А. А., Белоусова И. Б. Современные прокинетики и их роль в лечении гастроэнтерологических заболеваний. Клиническая медицина. 2016; 94 (3): 178–182.Johnston K. D., Lu Z., Rudd J. A. Looking beyond 5-HT3 receptors: A review of the wider role of serotonin in the pharmacology of nausea and vomiting. European Journal of Pharmacology. 2014; 722, 13–25.Johnston K. D., Lu Z., Rudd J. A. Looking beyond 5-HT3 receptors: A review of the wider role of serotonin in the pharmacology of nausea and vomiting. European Journal of Pharmacology. 2014; 722, 13–25.Brandt T. Vertigo. Its Multicensory Syndromes. London: Springer. 2000; 503 p.Brandt T. Vertigo. Its Multicensory Syndromes. London: Springer. 2000; 503 p.Babin R. W., Balkany T. J., Fee W. E. Transdermal scopolamine in the treatment of acute vertigo. Annals of Otology, Rhinology & Laryngology. 1984; 93 (1): 25–27.Babin R. W., Balkany T. J., Fee W. E. Transdermal scopolamine in the treatment of acute vertigo. Annals of Otology, Rhinology & Laryngology. 1984; 93 (1): 25–27.Wood C. D. Antimotion sickness and antiemetic drugs. Drugs. 1979; 17 (6): 471–9.Wood C. D. Antimotion sickness and antiemetic drugs. Drugs. 1979; 17 (6): 471–9.Salahudeen M. S., Duffull S. B., Nishtala P. S. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatrics. 2015; 15 (1): 1–14.Salahudeen M. S., Duffull S. B., Nishtala P. S. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatrics. 2015; 15 (1): 1–14.McCabe B.F., Sekitani T., Ryu J. H. Drug effects on postlabyrinthectomy nystagmus. Archives of Otolaryngology – Head and Neck Surgery. 1973; 98 (5), 310–313.McCabe B.F., Sekitani T., Ryu J. H. Drug effects on postlabyrinthectomy nystagmus. Archives of Otolaryngology – Head and Neck Surgery. 1973; 98 (5), 310–313.Soto E., Vega R. Neuropharmacology of vestibular system disorders. Current Neuropharmacology. 2010; 8 (1), 26–40.Soto E., Vega R. Neuropharmacology of vestibular system disorders. Current Neuropharmacology. 2010; 8 (1), 26–40.Huppert D., Strupp M., Mückter H., Brandt, T. Which medication do I need to manage dizzy patients? Acta Oto-Laryngologica. 2010; 131 (3), 228–241.Huppert D., Strupp M., Mückter H., Brandt, T. Which medication do I need to manage dizzy patients? Acta Oto-Laryngologica. 2010; 131 (3), 228–241.Левин О. С., Штульман Д. Р. Неврология. Спра- вочник практического врача. М.: МЕДпресс- информ, 2016, с. 200–215.Левин О. С., Штульман Д. Р. Неврология. Спра- вочник практического врача. М.: МЕДпресс- информ, 2016, с. 200–215.McClure J.A., Lycett P., Baskerville J. C. Diazepam as an antimotion sickness drug. Journal of Otolaryngology. 1982; 11 (4): 253–9.McClure J.A., Lycett P., Baskerville J. C. Diazepam as an antimotion sickness drug. Journal of Otolaryngology. 1982; 11 (4): 253–9.Zajonc T. P., Roland P. S. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear, Nose & Throat Journal. 2006; 85 (1), 25–35.Zajonc T. P., Roland P. S. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear, Nose & Throat Journal. 2006; 85 (1), 25–35.Funderburk F. R., Griffiths R. R., McLeod D.R., George E. Relative abuse liability of lorazepam and diazepam: an evaluation in “recreational” drug users. Drug and Alcohol Dependence. 1988; 22 (3), 215–222.Funderburk F. R., Griffiths R. R., McLeod D.R., George E. Relative abuse liability of lorazepam and diazepam: an evaluation in “recreational” drug users. Drug and Alcohol Dependence. 1988; 22 (3), 215–222.Halmagyi M. Vertigo and vestibular disorders. In: Eadie M. J., editor. Drug therapy in neurology. Edinburgh: Churchill Livingstone. 1992; 375–85.Halmagyi M. Vertigo and vestibular disorders. In: Eadie M. J., editor. Drug therapy in neurology. Edinburgh: Churchill Livingstone. 1992; 375–85.Miller A. D., Leslie R. A. The area postrema and vomiting. Frontiers in Neuroendocrinology. 1994; 15 (4).Miller A. D., Leslie R. A. The area postrema and vomiting. Frontiers in Neuroendocrinology. 1994; 15 (4).Barone J. A. Domperidone: a peripherally acting dopamine2-receptor antagonist. Annals of Pharmacotherapy. 1999; 33 (4), 429–440.Barone J. A. Domperidone: a peripherally acting dopamine2-receptor antagonist. Annals of Pharmacotherapy. 1999; 33 (4), 429–440.Saberi A., Pourshafie S. H., Kazemnejad-Leili E. et al. Ondansetron or promethazine: Which one is better for the treatment of acute peripheral vertigo? American Journal of Otolaryngology. 2019; 40 (1): 10–15.Saberi A., Pourshafie S. H., Kazemnejad-Leili E. et al. Ondansetron or promethazine: Which one is better for the treatment of acute peripheral vertigo? American Journal of Otolaryngology. 2019; 40 (1): 10–15.Redon C, Lopez C, Bernard-Demanze L, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011;51(4):538–548.Redon C, Lopez C, Bernard-Demanze L, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011;51(4):538–548.

The authors declare that there are no conflicts of interest present.